Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | NPY4R | P50391 | 11/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.48 |
| ▸ | NPY1R | P25929 | 8/20 | 0.48 |
| ▸ | NPY2R | P49146 | 6/20 | 0.48 |
| ▸ | FURIN | P09958 | 1/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168340 | 0.90 | RXFP1 (0.60) | TFPIRXFP1FURINIL23R | |
| SCHEMBL10168584 | 0.90 | RXFP1 (0.60) | TFPIRXFP1FURINIL23R | |
| SCHEMBL10168798 | 0.90 | TFPI (0.51) | TFPIRXFP1NPY4RNPY5RNPY1R | |
| SCHEMBL10168696 | 0.89 | RXFP1 (0.62) | TFPIRXFP1 | |
| SCHEMBL10169252 | 0.88 | RXFP1 (0.59) | TFPIRXFP1FURIN | |
| SCHEMBL10168669 | 0.88 | RXFP1 (0.59) | TFPIRXFP1 | |
| SCHEMBL10168283 | 0.88 | RXFP1 (0.59) | TFPIRXFP1FURIN | |
| SCHEMBL10168809 | 0.88 | RXFP1 (0.59) | TFPIRXFP1FURIN | |
| SCHEMBL10169113 | 0.88 | RXFP1 (0.59) | TFPIRXFP1FURIN | |
| SCHEMBL10168577 | 0.87 | RXFP1 (0.57) | TFPIRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | APLNR, AP1G1, AP2B1 | TFPI 2851/4885RXFP1 827/4885NPY4R 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.